polycystic ovary syndrome. Endocrine, nutritional and metabolic diseases(E00-E90)
Conditions
Interventions
Intervention 1: Experimental group: Diet and exercise program
Diet plan: at the beginning of study a check list prepared for each individual and weekly regimen recommended separately based on feeding
Lifestyle
Treatment - Drugs
Experimental group: Diet and exercise program
Diet plan: at the beginning of study a check list prepared for each individual and weekly regimen recommended separately based on feeding patterns and i
For controls group: The standard drugs
Diane: from fifth Day of cycle for 21 days every night, once a day
Spironolactone: 25 mg twice a day
Sponsors
Vice chancellor for research, Islamic Azad University of karaj branch
Eligibility
Sex/Gender
Female
Age
15 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1- Participants have body mass index= 25 kg/ m2; 2- All Participants treat with same dose of oral contraceptives pill and spirnolacton; 3- All Participants have menstrual pattern as oligomenorrhea (irregular bleeding episodes with intervals occur more than 35 days); 4- All Participants have suffered some degree of hirsutism. Exclusion criteria: 1- Use of any drug other than the standard drug for the treatment of polycystic ovary syndrome, which is the same for everyone. (Including drugs to treat infertility, diabetes, hormonal drugs, reduce appetite and etc); 2- Smoking; 3- Being in pregnancy and lactation period or pregnancy decision; 4- Having cardiovascular, renal, liver, respiratory diseases, diabetes, uncontrolled hypertension, malignancy or any other acute or chronic disease; 5- Prohibition of the exercise due to illness or any other cause according to physician order; 6- Participating in regular exercise before the start of the study; 7- Having a separate diet programs before the start of the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum testosterone(total & free). Timepoint: Before intervention - three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits.;Serum Dehydroepiandrosterone Sulphate (DHEAS). Timepoint: Before intervention - three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits.;Serum sex hormone binding globulin (SHBG). Timepoint: Before intervention - three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits.;Body mass index(BMI). Timepoint: Before intervention - three months after intervention. Method of measurement: By measuring the height (m) and weight (kg).;Hirsutism. Timepoint: Before intervention - three months after intervention. Method of measurement: Using Friedman and Galway scale.;Oligomenorrhea. Timepoint: Before intervention - three months after intervention. Method of measurement: Considering the menstrual cycle (irregular bleeding episodes with intervals of more than 35 days).;Ovary status. Timepoint: Before intervention - three months after intervention. Method of measurement: using abdominal ultrasound. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum Progestron. Timepoint: Before intervention - three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits.;Serum LH. Timepoint: Before intervention - three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits.;Serum FSH. Timepoint: Before intervention - three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits.;Serum stradiol. Timepoint: Before intervention - three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits.;Serum prolactin. Timepoint: Before intervention - three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits.;Serum T3. Timepoint: Before intervention - three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits.;Serum T4. Timepoint: Before intervention - three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits.;Serum TSH. Timepoint: Before intervention - three months after intervention. Method of measurement: Serological test with Electro Komolomynsans method with using of the company's ROCHE kits. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mani Mirfeizi
Islamic Azad University Karaj branch
Outcome results
None listed